BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) spotted trading -47.78% off 52-week high price. On the other end, the stock has been noted 39.05% away from the low price over the last 52-weeks. The stock changed -2.76% to recent value of $7.05. The stock transacted 52104 shares during most recent day however it has an average volume of 48.57K shares. The company has 9.55M of outstanding shares and 5.29M shares were floated in the market.
On March 24, 2020, BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) developer of the universal influenza vaccine candidate M-001, revealed that all proposed resolutions were approved at the Company’s Annual General Meeting held , including the election of three new directors to the Company’s Board of Directors, namely, Dr. Yael Margolin, Mr. Adi Raviv, and Mr. Samuel Moed.
Mr. Samuel Moed currently serves as Senior Vice President, Corporate Strategy at Bristol Myers Squibb (BMS;NYSE: BMY), a global biopharma company focused on innovative therapeutics, where for the past six years he has led the strategic direction of the company with close linkage to all of its major businesses, functions and geographies. Previously, Mr. Moed oversaw strategy for BMS’s Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of strategic alliances. He also led a number of businesses including as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare. Mr. Moed received a BA in history from Columbia University in New York City.
Its earnings per share (EPS) expected to touch remained -95.30% for this year.
According to the most recent quarter its current ratio was 25.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of -2.50% from the mean of 20 days, -21.29% from mean of 50 days SMA and performed 2.61% from mean of 200 days price. Company’s performance for the week was 17.30%, -19.61% for month and YTD performance remained -24.11%.